You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR CIMETIDINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cimetidine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002092 ↗ A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection Completed Community Research Initiative of New England N/A 1969-12-31 To determine the change in CD4 count after 4 and 8 weeks in HIV-infected patients treated with cimetidine compared to placebo. To observe time-associated trends at weeks 4, 8, 12, and 16 in the change of CD4 counts for patients taking cimetidine for the full 16 weeks. To establish a safety record for cimetidine use in HIV-positive patients.
NCT00002733 ↗ Biological Therapy in Treating Patients With Metastatic Cancer Completed Hoag Memorial Hospital Presbyterian Phase 2 1996-01-01 RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
NCT00038402 ↗ Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Completed Genentech, Inc. Phase 3 2001-04-01 The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00038402 ↗ Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Completed M.D. Anderson Cancer Center Phase 3 2001-04-01 The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cimetidine Hydrochloride

Condition Name

Condition Name for Cimetidine Hydrochloride
Intervention Trials
Healthy 5
Gastric Cancer 2
Breast Cancer 2
Rectal Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cimetidine Hydrochloride
Intervention Trials
Breast Neoplasms 3
Warts 3
Carcinoma 3
Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cimetidine Hydrochloride

Trials by Country

Trials by Country for Cimetidine Hydrochloride
Location Trials
United States 85
China 9
Germany 5
Canada 2
Egypt 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cimetidine Hydrochloride
Location Trials
Texas 13
Florida 4
Massachusetts 4
Washington 4
Illinois 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cimetidine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cimetidine Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cimetidine Hydrochloride
Clinical Trial Phase Trials
Completed 34
Unknown status 12
Recruiting 8
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cimetidine Hydrochloride

Sponsor Name

Sponsor Name for Cimetidine Hydrochloride
Sponsor Trials
M.D. Anderson Cancer Center 9
Assiut University 5
Genentech, Inc. 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cimetidine Hydrochloride
Sponsor Trials
Other 61
Industry 35
NIH 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Cimetidine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Cimetidine hydrochloride, a histamine H2 receptor antagonist, has been a cornerstone in the management of gastrointestinal disorders for several decades. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

Duodenal Ulcer Treatment

Cimetidine has been extensively studied for its efficacy in treating active duodenal ulcers. Clinical trials have shown that cimetidine accelerates the healing rate of duodenal ulcers. In U.S. and foreign controlled trials, oral cimetidine at doses of 800 mg taken at bedtime (h.s.) resulted in healing rates of 79 to 85% at four weeks[3][4].

Gastric Ulcer Treatment

Cimetidine has also demonstrated effectiveness in treating benign gastric ulcers. Worldwide double-blind clinical studies have consistently shown higher healing rates with cimetidine compared to placebo. For instance, one study reported a healing rate of 76% with cimetidine versus 55% with placebo at week 6[3].

Prevention of Upper Gastrointestinal Bleeding

In critically ill patients, cimetidine has been shown to reduce the incidence of upper gastrointestinal bleeding. A double-blind, placebo-controlled study found that 14% of patients treated with cimetidine continuous infusion developed bleeding, compared to 33% in the placebo group[3].

Mechanism of Action and Pharmacology

Histamine H2 Receptor Antagonism

Cimetidine works by competitively inhibiting histamine binding to H2 receptors on the basolateral membrane of gastric parietal cells, thereby reducing gastric acid secretion and gastric volume and acidity[2][4].

Metabolic Interactions

Cimetidine is known to inhibit many isoenzymes of the hepatic CYP450 enzyme system, which can affect the metabolism of co-administered medications. For example, it potentiates the anticoagulant effect of warfarin by reducing its metabolic clearance, unlike ranitidine which does not have this effect[1][2].

Market Analysis

Current Market Position

Cimetidine is widely available under various brand names, including Tagamet and Good Sense Heartburn Relief. It is used to treat and prevent conditions such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions. The drug is available in various dosage forms, including oral tablets and liquid[2][4].

Competitive Landscape

The market for H2 receptor antagonists is competitive, with other drugs like ranitidine (Zantac), famotidine (Pepcid), and nizatidine (Axid) also available. However, cimetidine remains a significant player due to its established efficacy and long history of use. Proton pump inhibitors (PPIs) like pantoprazole (Protonix) and esomeprazole (Nexium) also compete in the same therapeutic area but are generally used for more severe cases or when H2 antagonists are not sufficient[4].

Side Effects and Safety Profile

Common Side Effects

Common side effects of cimetidine include headache and diarrhea. Serious side effects, though rare, can include allergic reactions, changes in mood, confusion, hallucinations, and hematologic effects such as agranulocytosis and thrombocytopenia[3][4].

Contraindications and Warnings

Cimetidine is contraindicated in patients allergic to it or other H2 antagonists. It should be used with caution in patients with liver or kidney disease, and its use during pregnancy and breastfeeding is advised against unless absolutely necessary[4].

Market Projections

Future Demand

Despite the availability of newer PPIs, cimetidine is expected to maintain a stable market presence due to its well-established efficacy and safety profile. The demand for H2 antagonists is likely to remain steady, particularly for over-the-counter use in managing heartburn and acid indigestion.

Pricing and Accessibility

Cimetidine is generally priced lower than PPIs, making it a more accessible option for many patients. This affordability, combined with its effectiveness, will continue to drive its use in both prescription and over-the-counter markets.

Regulatory Environment

Regulatory changes and safety updates can impact the market for cimetidine. For instance, any new safety warnings or contraindications could affect its prescription rates. However, given its long history and extensive use, cimetidine is likely to remain a viable treatment option.

Key Takeaways

  • Efficacy: Cimetidine is highly effective in treating duodenal and gastric ulcers, GERD, and preventing upper gastrointestinal bleeding.
  • Mechanism of Action: It works by inhibiting histamine H2 receptors, reducing gastric acid secretion.
  • Market Position: Cimetidine remains a significant player in the H2 antagonist market despite competition from PPIs.
  • Side Effects: Common side effects are mild, but serious side effects can occur, particularly in vulnerable populations.
  • Projections: The demand for cimetidine is expected to remain stable due to its efficacy, safety, and affordability.

FAQs

What is cimetidine used for?

Cimetidine is used to treat and prevent conditions such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions.

How does cimetidine work?

Cimetidine works by competitively inhibiting histamine binding to H2 receptors on the gastric parietal cells, reducing gastric acid secretion.

What are the common side effects of cimetidine?

Common side effects include headache and diarrhea. Serious side effects can include allergic reactions, changes in mood, and hematologic effects.

Can cimetidine interact with other medications?

Yes, cimetidine can interact with other medications by inhibiting the CYP450 enzyme system, affecting the metabolism of co-administered drugs.

Is cimetidine safe during pregnancy and breastfeeding?

Cimetidine should be used with caution during pregnancy and is advised against during breastfeeding unless absolutely necessary.

What is the competitive landscape for cimetidine?

Cimetidine competes with other H2 antagonists like ranitidine and famotidine, as well as proton pump inhibitors (PPIs) like pantoprazole and esomeprazole.

Sources

  1. O'Reilly RA. Comparative Interaction of Cimetidine and Ranitidine With Racemic Warfarin in Man. Arch Intern Med. 1984;144(5):989–991. doi:10.1001/archinte.1984.00350170143024
  2. DrugBank. Cimetidine: Uses, Interactions, Mechanism of Action.
  3. Drugs.com. Cimetidine Injection: Package Insert / Prescribing Info.
  4. Drugs.com. Cimetidine Uses, Side Effects & Warnings.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.